These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
664 related items for PubMed ID: 28647837
1. Targeting metabolic reprogramming in KRAS-driven cancers. Kawada K, Toda K, Sakai Y. Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837 [Abstract] [Full Text] [Related]
2. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. Caiola E, Falcetta F, Giordano S, Marabese M, Garassino MC, Broggini M, Pastorelli R, Brunelli L. J Exp Clin Cancer Res; 2018 Dec 04; 37(1):302. PubMed ID: 30514331 [Abstract] [Full Text] [Related]
3. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis. Green S, Trejo CL, McMahon M. Cancer Res; 2015 Dec 15; 75(24):5378-91. PubMed ID: 26567140 [Abstract] [Full Text] [Related]
4. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian D, Li C, Zhang H, Wang S, Zhu J, Gao L, Zhang Q, Jia B, Hao L, Wang C, Zhang B. Oncotarget; 2017 Jan 03; 8(1):179-190. PubMed ID: 27329725 [Abstract] [Full Text] [Related]
6. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer. Liu S, Gandler HI, Tošić I, Ye DQ, Giaccone ZT, Frank DA. Mol Cancer Res; 2021 Aug 03; 19(8):1283-1295. PubMed ID: 33931487 [Abstract] [Full Text] [Related]
7. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Ohm AM, Tan AC, Heasley LE, Reyland ME. Oncogene; 2017 Jul 27; 36(30):4370-4378. PubMed ID: 28368426 [Abstract] [Full Text] [Related]
8. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, Lau AN, Ji BW, Dixit PD, Hosios AM, Muir A, Chin CR, Freinkman E, Jacks T, Wolpin BM, Vitkup D, Vander Heiden MG. Science; 2016 Sep 09; 353(6304):1161-5. PubMed ID: 27609895 [Abstract] [Full Text] [Related]
9. Critical role of oncogenic KRAS in pancreatic cancer (Review). Liu J, Ji S, Liang C, Qin Y, Jin K, Liang D, Xu W, Shi S, Zhang B, Liu L, Liu C, Xu J, Ni Q, Yu X. Mol Med Rep; 2016 Jun 09; 13(6):4943-9. PubMed ID: 27121414 [Abstract] [Full Text] [Related]
10. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets. Drosten M, Barbacid M. J Mol Med (Berl); 2016 Feb 09; 94(2):121-35. PubMed ID: 26526121 [Abstract] [Full Text] [Related]
11. Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells. Trinidad AG, Whalley N, Rowlinson R, Delpuech O, Dudley P, Rooney C, Critchlow SE. Oncogene; 2017 Nov 02; 36(44):6164-6176. PubMed ID: 28692044 [Abstract] [Full Text] [Related]
12. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer. Roh JI, Lee J, Sung YH, Oh J, Hyeon DY, Kim Y, Lee S, Devkota S, Kim HJ, Park B, Nam T, Song Y, Kim Y, Hwang D, Lee HW. Oncogene; 2020 Sep 02; 39(36):5876-5887. PubMed ID: 32728173 [Abstract] [Full Text] [Related]
13. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Ricciuti B, Leonardi GC, Metro G, Grignani F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A, Zicari D, Crinò L. Expert Rev Respir Med; 2016 Sep 02; 10(1):53-68. PubMed ID: 26714748 [Abstract] [Full Text] [Related]
14. CD44 promotes Kras-dependent lung adenocarcinoma. Zhao P, Damerow MS, Stern P, Liu AH, Sweet-Cordero A, Siziopikou K, Neilson JR, Sharp PA, Cheng C. Oncogene; 2013 Oct 24; 32(43):5186-90. PubMed ID: 23208496 [Abstract] [Full Text] [Related]
15. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Zhang J, Park D, Shin DM, Deng X. Acta Biochim Biophys Sin (Shanghai); 2016 Jan 24; 48(1):11-6. PubMed ID: 26578706 [Abstract] [Full Text] [Related]
16. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Nature; 2016 Mar 03; 531(7592):110-3. PubMed ID: 26909577 [Abstract] [Full Text] [Related]
17. Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations. Fritsche-Guenther R, Zasada C, Mastrobuoni G, Royla N, Rainer R, Roßner F, Pietzke M, Klipp E, Sers C, Kempa S. Sci Rep; 2018 Jun 15; 8(1):9204. PubMed ID: 29907857 [Abstract] [Full Text] [Related]
18. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. Bournet B, Buscail C, Muscari F, Cordelier P, Buscail L. Eur J Cancer; 2016 Feb 15; 54():75-83. PubMed ID: 26735353 [Abstract] [Full Text] [Related]
19. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Kerk SA, Papagiannakopoulos T, Shah YM, Lyssiotis CA. Nat Rev Cancer; 2021 Aug 15; 21(8):510-525. PubMed ID: 34244683 [Abstract] [Full Text] [Related]
20. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Caiola E, Brunelli L, Marabese M, Broggini M, Lupi M, Pastorelli R. Oncotarget; 2016 Aug 09; 7(32):51462-51472. PubMed ID: 27283493 [Abstract] [Full Text] [Related] Page: [Next] [New Search]